In this Pain and Cancer axis, my research activity focuses on the physiopathological mechanisms of peripheral neuropathies induced by chemotherapy treatments (CINP) causing disabling symptoms in patients and for which the need for medical innovation is important and not satisfied. The study of changes in expression and function of ion channels such as HCN channels but also of receptors for mediators expressed in peripheral neurons (DRG-TG) is necessary to better understand variations in neuronal activities and ultimately the rapid onset of symptoms and their chronicization. The implementation of new cellular models (IPSCs, organoids); The use of validated preclinical models of NCI and various techniques, notably imaging and electrophysiology, allow us to more precisely study these molecular targets of interest and determine their pharmacological potential to reduce NCI in patients.

• Biophysics, pharmaceutical biomathematics department: Pharmacy (DFGSP, DFASP, Internat);
• PASS/PASS-R;
• Bachelor’s degree in Life science – Pharmacology and Nutrition;
• Orthoptics 1st and 2nd year;
• Speech therapy 3rd year;
• Thesis and M2 co-supervision.

• Member of the UFR Pharmacy Council;
• Certificate of Pharmaceutical Synthesis (CSP) working group.

https://orcid.org/0009-0004-8195-3395

• Pharmacological modulation of HCN channels activity decreases oxaliplatin-induced peripheral neuropathy symptoms. E. Wersinger E, K. Delanoe K, M. Morez et al., J Periph Nerv Syst. 2023;28 (Suppl. 4):S128
• Modulation of HCN channel activity in oxaliplatin-induced peripheral neuropathy. M. Morez, Y. Aissouni, L. Prival, J. Barbier, D. Balayssac, et al., Fundamental & Clinical Pharmacology, 2022;36 (S1), pp.10-11